Nekuino, a Japan-based medical technology developer backed by corporate investors All About, Nippon Life, KLab and Credit Saison, secured an undisclosed amount from venture capital firm Jafco yesterday.
Jafco led a round that pushed the company’s overall funding to ¥2bn ($19.2m) since it was founded in 2016 as Next Innovation. The other investors in the round were undisclosed.
Nekuino provides teleconsultation services and remote medical examinations catering to patients’ lifestyles and health conditions. Its lead product, Smaluna, was launched in 2018 and focuses on gynaecology.
Jafco had already led a series A round of undisclosed size for the company in 2019, investing alongside online information portal All About, Nippon Venture Capital and Japan Startup Support Association.
Nekuino secured $960,000 the year before from Nissay Capital, KLab Venture Partners (now called Anobaka) and Saison Ventures, on behalf of insurer Nippon Life, mobile game producer KLab and payment services firm Credit Saison respectively, as well as Future Venture Capital’s Anabuki Startup Support Fund and Venture United.
